Pacific Hearing Connection

What do they do? Pacific Hearing Connection offers reduced-fee hearing assessment, hearing aids and follow-up in the Bay Area, alongside outreach and education. More

Why this approach interests us

• Appropriately fitted hearing aids can improve communication for people who would otherwise remain untreated.
• Donated devices, professional time and space can help make care more affordable.
• An operating service and named clinical leadership provide a practical local route to treatment.

Our main reservations

• Annual unique fitted patients and the additional treatments funded by a new donation are not established by public records.
• Estimated health gains depend strongly on duration, utility and favorable scenarios; donated resources are not fully costed.

What do you get for your dollar? The central scenario is about $2.20 million per 10 Bay Area QALYs. A separate probability-weighted illustration is about $938,000, but depends heavily on its favorable scenario and should not be substituted for the central estimate. More

Organization and current delivery

The legal recipient is Pacific Hearing Connection, not the similarly abbreviated Project Homeless Connect, the Hearing and Speech Center, Ear of the Lion, or the for-profit Pacific Hearing Service. The official donation page identifies EIN 81-2591375. The current homepage describes low-cost, sliding-scale services and a local mission. It does not promise free hearing aids to all applicants. Hearing screening and education sit alongside clinical care; the ordinary gift supports the organization, not a ring-fenced clinical course by default.

The FAQ describes income and asset review, refurbished aids, possible new-device purchase when stock is unsuitable, donated office space and clinician time from Pacific Hearing Service, and community-service expectations with an accommodation involving family or friends. These are important implementation details. Donated hardware alone is not the service package. Assessment, appropriate selection, fitting, counseling, maintenance and follow-up can determine whether a device is useful. The exact volume of each service and the proportion of recipients successfully completing the package remain unavailable in the inspected public materials.

The clinical team and community-partner list support the existence of an operating network. They do not identify spare appointment slots, the marginal staffing bottleneck, a waiting list's urgency, or the outcomes of referred patients. A named partnership can mean outreach, a referral relationship, a venue or funded delivery. We do not count all partner clients as Pacific Hearing Connection patients. Nor do we count every hearing aid donated as a fitted person: devices can be repaired, traded for credit, held in inventory, paired for bilateral fitting or found unsuitable.

Geography and overlapping organizations

The organization says most patients are from the Bay Area, with occasional exceptions. A Kaiser Permanente 2025 community-benefit report, PDF page 9, describes services in Santa Clara and San Mateo counties. Neither source supplies a residence-weighted annual denominator. The model's 85%, 95% and 99% Bay shares are therefore priors informed by local scope, not measured percentages. We do not turn office addresses or partner addresses into recipient residence data.

There is no assumed new outcome for a patient already credited through another hearing provider. A bilateral fitting is one person-level health effect. If a person moves between Pacific Hearing Connection, another charity, insurance-funded care and a private provider, the model should count only the incremental improvement attributable to the evaluated service compared with that actual alternative. Separate charity pages are alternative evaluations, not additive population estimates. Their modeled health totals should not be summed without a common patient and counterfactual ledger.

This distinction also matters for joint fundraising. If one organization refers and another fits the same patient, both activities may be necessary, but both cannot independently claim the entire resulting improvement. A joint gift requires an allocation or causal-complement model. Our standalone estimate uses a funding-response assumption and finite alternative-care exposure; it is not evidence that this recipient owns all benefit in a multi-provider chain.

Three years of finances

The latest original return located in the current index is FY2024, submitted October 15, 2025. We also inspected original FY2023 and FY2022 returns and their Schedule O explanations. No FY2025 return was located in this bounded check. That is a limitation of the available evidence, not a claim that the organization failed to file. Amounts below are reported accounting amounts, not an independently audited cash-flow reconstruction.

Pacific Hearing — natural expense shares

Whole reported expense denominator. Other includes inventory adjustment; program-service expense is an overlapping functional classification, not added here.

Shares are calculated as category expense divided by the stated annual denominator. Rounding may make displayed shares differ slightly from 100%.

Sources: original FY2022 return, FY2023 return, FY2024 return, and their Schedule O links in the source ledger. Revenue is contributions plus program-service revenue in these returns. Program-service revenue is not proven to be entirely patient fees. We retain gross whole expense rather than subtracting fees from costs while ignoring their role in financing the service.

What changed inside expense

The FY2024 Schedule O itemizes $63,205 of other expenses. Its largest entry is a $45,900 inventory-cost adjustment; it also includes $6,300 hearing-aid cost of goods, $979 depreciation and smaller operating costs. The inventory balance declined by $15,150 from the prior year, which is not the same number as the adjustment. Receipts, use, write-downs or other flows would need reconciliation before inferring device throughput. There is no legitimate conversion from that adjustment to a count of newly treated patients.

The FY2023 Schedule O reports $17,562 outreach expense within its $26,332 other-expense total, alongside payment, technology, insurance, equipment-related and other costs. FY2024 separately reports much less outreach expense while contractors increase. These accounting categories may shift across years and are not a comparable time series of service capacity. The FY2022 Schedule O itemizes $6,832 of other expenses including outreach, audiology equipment, payment and operating items.

A donor might reasonably ask whether the inventory adjustment should be excluded from a forward-looking cash budget. The answer is that a forward budget should reconcile it, not silently delete it. The adjustment may be noncash in the reported year, but maintaining the productive stock can still use real resources. Conversely, adding retail donated-device value on top of a booked inventory expense could double-count the same resource. We preserve the whole accounting denominator and show a removal diagnostic separately. It is not labeled a cash estimate.

Reserves and a current budget

FY2024 ended with $241,791 net assets and $163,983 cash/savings/investments. Those balances do not prove unrestricted, currently spendable surplus. They also do not support assuming that every additional dollar is immediately required for patient care. Restrictions, commitments, payroll timing, stock needs and subsequent operations could materially change available capacity. No current management budget, reserve designation schedule or grant-balance reconciliation was found.

The difference between whole expense and program expense is retained. An ordinary gift finances administration and fundraising as well as service delivery; extracting only a favorable clinical slice would change the question. At the same time, a high program-expense fraction is not causal evidence. A well-classified expense can still fund an activity that produces little additional health, while necessary administration may enable high-value service. Financial ratios identify accounting boundaries, not treatment effects.

The three-year expense series is useful because it prevents a misleading static picture of a permanently low-cost clinic. It does not establish a trend to extrapolate. The later grant-supported education initiative may expand the organization, reallocate staff time, or finance work already underway. Since its realized expenditure and treatment cascade are missing, V2 does not replace the latest filing with a speculative sum of awards. The $184,099 denominator remains a historical whole-expense proxy with an explicit current-budget caveat.

Clinical evidence and its limits

Short-term hearing-sensitive utility

Kaur and colleagues studied a delayed-start hearing intervention in Singapore, analyzing 264 fitted and 163 delayed participants. Their reported three-month HUI3 difference was about 0.12. Community-level allocation, selected interested participants and a modified questionnaire for controls limit transfer. The study's longer-horizon cost-effectiveness results were modeled; they are not directly observed Bay QALYs. Its one-year follow-up reached about 66%, and 71.4% of respondents reported continued use. Missing responses prevent treating that as a complete-cohort adherence rate.

The model uses 0.12 as an external endpoint utility anchor, not 0.12 QALYs per fitting or per quarter. A utility gain must be integrated over incremental useful time. If a 0.12 difference were constant for a quarter, the undiscounted area would be 0.03 QALYs before other adjustments—not 0.12. The present model further applies a population/service transfer and offer-to-completion conversion. These reductions are explicit judgments, not statistics estimated from this clinic's patients.

The distinction between a fitted-person result and an offer-level result is essential. A completed-fit study may omit people who never initiate or finish care. Applying its effect to all referrals would overstate benefit. Conversely, if a study's intention-to-treat estimate already includes dropout, multiplying by the same dropout proportion again would understate it. Our model's completion parameter converts hypothetical commissioned offers to completed fitting; its effective years cover subsequent incremental exposure. Neither is claimed to be the original trial's causal estimator.

Generic health measures and sustained communication

The ACHIEVE quality-of-life analysis included 977 older adults. Over three years, the physical and mental RAND-36 component differences were 0.43 (95% CI −0.64 to 1.51) and 0.47 (−0.41 to 1.35): neither established an overall component benefit. Some individual domains favored intervention. RAND-36 points are not QALYs. During follow-up, 15.6% of controls obtained hearing aids and 2.0% of intervention participants discontinued, underscoring the importance of actual alternative care.

The communication analysis supports sustained hearing-related improvement with a supported trial package. The shared evidence review records a roughly nine-point HHIE-S difference and average logged use of 6.6 hours daily across follow-up. This does not supply a HHIE-S-to-utility conversion. The main trial involved selected older adults, structured audiology support and reinforcement. A locally delivered package may differ in patient mix, intensity, continuity and comparator access.

Barton and colleagues' 2004 before-and-after study of 609 adults found changes of about 0.06 using HUI3 and 0.01 using EQ-5D or SF-6D. The publisher's later online date should not be mistaken for the study year. This nonrandomized comparison motivates instrument-specific diagnostics; it does not establish a causal local effect or a confidence interval around 0.01–0.12. The 0.06 case retains the historical transfer multiplier rather than silently treating an observational change as fully transportable.

These studies should neither be averaged into a fabricated local utility nor used to declare that all hearing benefits are zero. Hearing-sensitive and generic instruments capture different constructs with different sensitivity. The model consequently retains its historical hearing-sensitive branch and exposes lower-utility diagnostics. No extra social-functioning, cognition, employment or mortality benefit is stacked onto hearing utility. Such stacking could count the same improvement more than once, and the sources here do not establish an independent local effect.

Finite duration, adherence and harms

Effective years mean the discounted area of useful health improvement relative to the actual alternative, not the shelf life of a hearing aid. It incorporates ramp-up, post-fitting nonuse, mortality, repair interruptions and eventual alternative treatment. The central 0.5 effective years and favorable two effective years are judgmental. Two effective years can fit within a supported finite multi-year episode, but it is not a measured local duration or a two-year HUI3 observation. The model does not award a fresh full horizon for each replacement aid or follow-up visit.

A person who would obtain equivalent treatment next month has a much shorter incremental exposure than someone who would otherwise remain untreated for years. We therefore distinguish donor-created service capacity from alternative-care timing. The funding parameter asks whether the gift adds commissioned offers; effective years ask how much better the patient's health trajectory is once an offer is added. The same lost opportunity must not be subtracted in both places. The factorized model cannot fully represent their correlation, so its weights are not empirical probabilities.

Nonuse is primarily forgone benefit, not automatically harm. A separate signed harm allowance represents incremental burdens not already reflected in utility or lost exposure. It is hypothetical, not a measured adverse-event rate. Discomfort, unsuitable amplification, travel or service burdens may matter, but direct monetary and time costs are not casually converted into QALYs. A negative world keeps the possibility visible without pretending to have local incidence data. Trial safety reporting does not establish zero harm in a different population and delivery setting.

Research provenance and model boundary

This assessment was reviewed September 11, 2026 using public sources. We did not contact the organization or review private monitoring records.

The original model and its first saved result are preserved separately. V2's wrapper adds validation for whitespace-equivalent scenario identities and nonfinite derived shares, with exact default-result parity. The accompanying data includes all worlds, diagnostics, three years of finance, source links and explicit unknowns. Probability weights remain subjective and were not changed to cross a ranking threshold. Full model version: pacific-hearing-connection-depth-v2-unchanged-base; historical calculation version retained inside the parity-locked result.

What would change our view?

The most informative evidence would link financing to distinct patient trajectories. An annual tally alone would reduce throughput uncertainty but would not establish additionality. A funded-versus-unfunded appointment plan alone would clarify capacity but not sustained benefit. Follow-up on selected success stories alone could overstate typical use. A modest linked dataset can address all three: eligible offers, completed fitting, alternative access, useful follow-up and the resources used.

We would not require a local randomized trial before improving this estimate. Good operational evidence could justify narrower volume, completion and duration priors. A transparent marginal budget could narrow the funding-response assumption. External clinical evidence could still provide an explicitly imperfect bridge. Conversely, a report that only enlarges outreach reach or repeats fundraising illustrations would not justify a favorable numerical revision.

The prior-driven base remains unchanged because the new evidence does not uniquely select different coefficients. This is not a claim that the old priors are now verified. The V2 improvement is a more complete account of finances, alternatives, funded baseline, clinical interpretation and what would be needed to act. Publication as an exploratory comparison is reasonable; presenting the estimate as a purchasable marginal return is not.

We retain partial health scope. Education, community connection, ear-wax treatment, pediatric development, employment and partner effects are not assigned separate health credit. Their omission can matter, but unspecified benefits are not a reason to assume an excellent total return. Current donor capacity and full-resource cost remain explicitly null in structured data. The selected-world expectation is one transparent lens, not the organization's total value.

Model and results

The historical executable model is preserved. V2 adds a wrapper, financial data, source mapping, diagnostics and validation without changing its preferred coefficients or saved output. The equation is:

Bay QALYs = gift / whole expense × annual person-course offers × funding response × (utility × clinical transfer × completion × effective incremental years − harm per offer) × Bay share.

The whole-cost denominator and the annual person-course denominator describe the same organization-year abstraction. There is no extra clinical allocation multiplier: outreach, education, administration and other costs are already retained while only hearing-treatment health is credited. Adding another unexplained fraction would double-dilute; crediting outreach separately without a causal cascade would overstate benefits.

For $10,000, proportional annual offers are about 4.074; funding response reduces these to about 2.037 additional offers. The central net Bay effect is 0.022325 QALYs per additional offer, yielding 0.0454748532 Bay QALYs and $2,199,017.54 per 10. Arithmetic precision does not imply input precision: two or three significant figures are more meaningful in prose.

The selected worlds have weights 20% funding null, 20% clinical null, 10% harmful, 20% cautious, 20% central and 10% favorable. The favorable world assumes 150 offers, 75% funding response, 75% transfer, 90% completion, two effective years and 99% Bay share. Those favorable inputs move together. This is an explicit optimistic conjunction, not six independent events whose probabilities were estimated and multiplied.

Expected signed Bay QALYs are calculated before inverting to cost-effectiveness. The weighted result is 0.1066415353 QALYs per $10,000, or $937,720.93 per 10. Averaging scenario prices would mishandle null and harmful worlds and answer a different question. Null or harmful scenarios have no positive cost-per-10 figure; they are not assigned an artificial huge finite price to hide them in an average.

The favorable world contributes 91.7885% of net expectation, despite only 10% subjective mass. Excluding it and renormalizing the others yields approximately $10.28 million per 10. The selected-world mass below $1 million is 10%; below $100,000 it is zero. These are bookkeeping properties of chosen scenarios, not calibrated chances that a donation meets the thresholds. The base barely clearing $1 million therefore does not justify a confident recommendation.

Diagnostics, not alternative recommendations

The lower expense cases are not endorsed replacements. They show why the inventory and current-budget questions matter. The lower utility and shorter duration cases reveal that clinical interpretation matters much more than small accounting refinements. Combining 0.01 utility with a quarter-year cap leaves very small signed expected benefit and produces a price above $200 million. That unstable inverse should be read as near-zero modeled benefit under that combination, not a precise forecast of an enormous cost.

What throughput would be needed?

At the central per-additional-offer benefit, a $10,000 gift needs about 4.48 genuinely additional offers to reach $1 million per 10 QALYs, and 44.8 to reach $100,000. Under the central 50% funding response and whole-expense denominator, that corresponds to about 165 and 1,649 annual gross person-course offers respectively. The latter exceeds the model's allowed 1,000-offer input domain; it is a threshold diagnostic, not a proposed scenario or evidence of capacity.

These thresholds are useful questions for the organization. They are not targets to tune the prior toward. A more severe population or better sustained response could lower the required number; shorter benefit or better alternative access could raise it. A credible patient ledger plus a marginal staffing budget would allow those tradeoffs to be evaluated. At present, the model does not establish even its central 75 annual offers from public data.

Whole resources and the ordinary gift

The reported denominator includes unsuccessful assessment, outreach and nonmodeled activities. This is deliberately broader than a device-price calculation. A refurbished pair is not a whole treatment course, and an advertised contribution amount is not a guaranteed incremental outcome. The official donation examples include maintenance, tests, molds, refurbished aids and portable equipment. Those categories explain possible uses, not a contract specifying what the next gift buys.

The service also depends on resources outside the accounting denominator: donated professional time and space, device stock, patient contributions, travel and potentially other funders' work. Some devices may already be represented in inventory expense. Complete resource accounting would identify what is booked, what is unbooked, whether donated inputs have an opportunity cost, and whether incremental scale requires replacing free capacity with paid capacity. The illustrative 50% allowance is deliberately not called a measured societal estimate.

Ordinary gift allocation is unresolved. A new donation might support fitting, keep existing services running, fund education, cover a future equipment replacement or increase reserves. Funding response is not simply the percentage of expense labeled program. An organization can have a high program ratio yet little immediate additional capacity, or a low ratio while a small missing staff expense unlocks substantial service. We use a bounded prior rather than infer response from financial classification.

Neither patient fees nor grants are automatically donor leverage. Fees can subsidize care, but can also delay completion for cash-constrained patients. Grants can create productive capacity, but may already pay for the relevant expansion. Free stock can reduce cash costs, but may be unsuitable or unavailable at the margin. The right question is a with-gift versus without-gift service plan, including all complements and constraints. That plan was not found in the public record.

Funding and monitoring

Verified funding evidence, not a verified offer

The Santa Clara County Health Authority, associated with Santa Clara Family Health Plan, is the correct publisher of the March 27, 2025 governing-board minutes. It is not the Housing Authority. The consent calendar ratified a January committee approval of $129,987 for Hearing Heroes training, education and mobile screening from its board-designated CBO project fund. This is historical approval, not proof of remaining funds or new completed fittings.

Ability Central's 2026–2027 portfolio lists continued education, training materials and hearing screenings. The current listing does not disclose an amount or a patient outcome ledger. Its January 14, 2025 award announcement is a separate historical source; the old URL now redirects to a general philanthropy page, while the indexed historical excerpt remains available. We do not assume that successive listings are independent additive awards with identical amounts, nor identify the $26,500 year-end receivable as a particular grant without reconciliation.

An earlier El Camino Health application summary, PDF pages 183–184, described targets including 500 individuals, 85 services and 175 follow-ups and a $25,000 request recommended not to fund. Targets are not observed completed treatment. The denominators can overlap, and a follow-up can concern a previously fitted person. No model volume is derived from summing these figures. Later evidence of an operating program does not retroactively turn a proposal into measured achievement.

The Kaiser report provides independent funder corroboration of local clinical activity, but no unique completed-course denominator in the inspected passage. Taken together, the sources make a functioning, funded service more credible. They do not establish that another unrestricted dollar is the binding constraint. It would be equally mistaken to call them proof of no need: restricted training funds may not pay for fitting, and donations may complement them. Their restrictions, balances and planned use are the missing evidence.

Best existing alternatives

DHCS describes Medi-Cal hearing benefits including aids, fitting and repairs subject to rules and exceptions. HACCP eligibility rules describe a separate children's coverage route. Eligibility is not the same as finding a participating provider and receiving timely appropriate care. But the model cannot assume no equivalent public option for every low-income applicant. Patient age, insurance, coverage denial and waiting time are decision-relevant local variables.

The FDA's OTC guidance identifies a direct-purchase alternative for adults with perceived mild-to-moderate hearing loss, not children or severe/profound loss. It may reduce delay for some people and be unsuitable for others. We do not assign a retail device price or universal substitute rate without a matched population and service comparison. Private audiology, other charities and continued nonuse are also possible alternatives. Their probabilities and timing are not observed here.

Three questions before treating this as a giving recommendation

1. For the latest completed year and current year to date, how many distinct Bay residents were offered a fitting course, completed an appropriate fitting, and reported or logged useful use at three and twelve months? Please separate screenings, bilateral devices, repairs, repeat visits and externally completed referrals, and identify feasible alternative care.
2. What exactly would an additional unrestricted $10,000 change over the next twelve months compared with already committed operations? Please reconcile staff capacity, grant restrictions and balances, reserves, patient fees, device inventory and donated professional time, with a dated spending plan and expected additional completed patients.
3. Which resources are already included in reported expense and which are donated or paid by patients/partners? Please reconcile the FY2024 inventory adjustment and later stock movements, and explain whether scaling requires paid replacement of currently donated inputs.

Those questions are intentionally specific enough to falsify the favorable case. If the answer is that the gift only replenishes unrestricted reserves while planned service remains unchanged, immediate treatment additionality may be near zero. If a small staffed fitting block is demonstrably unfunded and has eligible patients with poor alternatives, the case could improve. Neither answer can be inferred from a general appeal. No outreach was performed in this review.